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Abstract  
Dietary advice and intervention do clearly have a place in rheumatology and allow patients to 
have some control over their own disease.  Though there is no evidence of efficacy of ‘fad’ 
diets, 30-40% of rheumatoid patients can benefit from excluding foods individually identified 
during the reintroduction phase of an elimination diet.  A proportion of patients that follow a 
vegetarian or Mediterranean-type diet will experience benefit.  Patients that are either 
overweight or obese should participate in weight-loss programmes.  Those with osteoarthritis 
need to concentrate on reducing fat mass, but maintaining muscle mass.  Arthritic patients, 
other than those with gout, should increase their intake of oily fish and additionally 
supplement with fish oil for up to three months to see if they experience benefit.  All arthritic 
patients, particularly those with inflammatory disease should be advised to ensure a good 
dietary intake of antioxidants, copper and zinc.  Supplementation with selenium and vitamin 
D may be advisable. 
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The use of diet to help control pain and symptoms of disease in musculoskeletal conditions is 
of great interest to patients because it is one way in which they can do something to help 
themselves.  Though patients always ask about whether making alterations to their diet will 
help, rheumatologists have traditionally been sceptical, dismissing the idea that dietary 
manipulation might be effective.  This is largely because of the paucity of evidence from well 
designed randomised studies.  However, results from randomised controlled trials reflect 
aggregated findings from many subjects and may be missing possible benefits to individual 
patients and their specific needs.  Doctors receive very little nutritional education and are 
therefore ill-equipped to advise on nutritional matters at an individual level.  Even where they 
are open-minded, there is a shortage of dietitians to whom patients might be referred and even 
fewer have relevant experience.  Though there is much self-help material available both in 
books and on-line for arthritis sufferers, little of it is well-informed and so they are at the 
mercy of marketing ploys that exploit their vulnerability.   We aim to show here that dietary 
advice and intervention do clearly have a place in rheumatology so that patients can be 
provided with evidence-based recommendations on diet and supplements that may help to 
reduce the risk of disease progression and relieve symptoms in a risk-free manner.   
 
Having critically examined some popular nutritional approaches, we will assess the evidence 
for the use of exclusion, elemental, vegetarian/vegan diets followed by a consideration of the 
impact of BMI, and the importance of fatty acids and micronutrients in arthritic conditions. 
 
 
 
Fad diets 
In practice, dietary modifications based on ‘fad’ diets may actually conflict with evidence-
based dietary advice for arthritis and other clinical conditions, thus adding confusion and the 
potential for impairing nutritional status.  Despite this, there is a huge amount of dietary 
advice aimed at people with arthritis. The vast majority of claims made by self-styled diets 
such as The Dong Diet, Sister Hills Diet and Norman F Childers Diet are unsubstantiated by 
science and based on individual experience, there being no evidence of objective overall 
clinical benefit [1].  However, data are consistent with certain types of dietary manipulation 
being beneficial for a subset of patients. 
 
 
 
Dietary manipulation  
Many patients have a poor response to, or are unwilling to tolerate the side effects of highly 
toxic drugs for long periods and often seek out other potential remedies such as dietary 
manipulation.  Up to 75% of patients believe that food affects their condition [2].  For 
instance, there is a common belief that tomatoes and citrus fruits are ‘acidic’ and that 
consumption will exacerbate joint inflammation.  In fact these foods have a pH raising 
(alkalinising) effect on the bloodstream, are rich in antioxidants such as vitamin C, lycopene 
and β-cryptoxanthin and should be included in a healthy diet.   
 
Self-imposed dietary exclusion is common in arthritic subjects and a dietary elimination 
programme designed to identify ‘offending’ foods is popular with patients.  Specific dietary 
approaches such as vegan, vegetarian or Mediterranean diets or at the most extreme, an 
elemental diet have also been tried in rheumatoid arthritis (RA) [3].  Studies of this nature 
have not been carried out in osteoarthritis (OA) patients therefore there is no evidence of 
efficacy in OA. 
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Exclusion Diet for RA 
There is evidence that patients can benefit from excluding foods individually identified during 
the reintroduction phase of an elimination diet.  Darlington and colleagues [4] carried out a 
blinded, placebo-controlled study of food elimination in 53 rheumatoid patients.  All subjects 
followed an exclusion phase for seven to ten days during which they ate a small range of 
rarely-eaten foods.  Foods were then introduced, one by one, to see which ones caused 
symptoms.  Any foods provoking reactions during the reintroduction phase were identified as 
culprit foods and avoided thereafter.  Culprit foods varied from one individual to the next.   
Forty-four subjects finished the trial.  Of these, 36% felt that after food exclusions they were 
much better and 39% felt they were better.  Objective measurements provided support for 
these findings: decreased pain and number of painful joints, reduced duration of morning 
stiffness, shorter time to walk 20 yards, better grip strength and improved ESR, haemoglobin, 
fibrinogen and platelet levels.  Improvement on dietary therapy was found to be independent 
of weight loss [5].  Foods found most likely to cause intolerance by Darlington and Ramsey 
[5] are listed in Table 1.  A more detailed explanation of the exclusion diet for RA is 
available elsewhere [3]. 
 
 
The Elemental Diet in RA 
An elemental diet comprises mono/di-saccharides, amino acids, medium chain triglycerides 
and is supplemented with vitamins, minerals and trace elements.  The diet is nutritionally 
complete and ‘non antigenic’.  It can be taken as an oral drink or administered by naso-enteric 
tube.  The taste is not particularly pleasant although the flavours are becoming increasingly 
more palatable.  Elemental diets have consistently been shown to induce improvements in 
subjective measures of RA symptoms in a sub-set of patients, with deterioration and return to 
baseline symptoms once the normal diet is re-introduced [6] [7] [8].  However, elemental 
diets are poorly tolerated though they may be used on a temporary basis as a diet of last 
resort.  
 
 
Fasting, vegetarian and vegan diets in RA 
Fasting appears to have an anti-inflammatory effect and confers pain relief during the fasting 
period [9] [10].  When eating is resumed, however, symptoms usually return.  An alternative 
is a regime of fasting followed by a vegetarian diet.  A systematic review of studies 
investigated the efficacy of this diet therapy [11].  Only four of 31 studies identified were 
independent controlled studies of fasting followed by a vegetarian diet for 3 months or more.  
The collective results showed statistically and clinically-significant, long-term benefits to 
patients. 
 
The ‘Mediterranean’ diet  
The ‘Mediterranean diet’ reflects the dietary patterns characteristic of several countries in the 
Mediterranean basin during the 1960s.  Typically the diet comprises abundant plant foods 
(including fruits, vegetables, wholegrain cereals, beans, nuts and seeds), minimally-processed, 
seasonally-fresh and locally-grown foods, fish and poultry, olive oil as the main source of 
lipid with dairy products, red meat and wine in low to moderate amounts [3]. Thus, the diet is 
rich in long chain n-3 polyunsaturated fatty acids (PUFA) and oleic acid (n-9 
monounsaturated), antioxidant nutrients and unrefined carbohydrates. 
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Two recent studies of very different populations have reported clinical benefits in RA patients 
who adopted a ‘Mediterranean-type’ diet [12] [13].  In a randomised, controlled, parallel 
study, Swedish patients with RA (n=26) who followed a modified Mediterranean (traditional 
Cretan) diet for three months reported a significant reduction in DAS28 and HAQ scores and 
in quality of life.  No significant change was seen in controls following a regular diet (n=25) 
[12].  Women with RA from socially deprived areas of Glasgow (n=75) completed a 6-week 
educational programme with an emphasis on cooking and eating a ‘Mediterranean type’ diet.  
Controls (n=55) were given general healthy eating information only.  Women in the 
intervention group reported a healthier dietary intake and showed significant benefits 
compared with controls for patient global assessment at 6 months; pain score at 3 and 6 
months, early morning stiffness at 6 months and HAQ at 3 months [13]. 
 
 
Possible explanations for clinical improvements using diet therapy in RA  
A number of explanations have been put forward to explain the benefit of dietary therapy of 
which some of the more plausible are outlined below. 
 
Elimination of foods to which the patient is allergic or intolerant: e.g. a gluten-free vegan 
diet regime in 66 patients with active RA reduced IgG antibody levels against gliadin with 
41% of patients fulfilling the ACR20 improvement criteria compared to only 4% in the non-
vegan diet controls [14]. 
 
Reduction in gastrointestinal permeability to bacterial and other antigens: Increased gut 
permeability, a result of the gut inflammation that exists in up to 67% of RA patients [15], 
possibly exacerbated by NSAID and DMARD treatment, can allow the passage of lumenal 
bacteria and polypeptides.  These may be absorbed in quantities sufficient to produce 
immunological responses leading to overt expression of RA [5].  Highly spiced foods, cereal 
grains, lectins (from legumes/cereals) strong coffee or tea and alcohol can increase gut 
permeability.  Avoiding these items could reduce GI permeability thus reducing disease 
symptoms. 
 
Alteration in gut flora: The intestinal flora of RA patients differs from those of non-RA 
controls and patients appear to maintain a high frequency of small intestinal bacterial 
overgrowth [15].  Changes in faecal flora brought about by a vegetarian or vegan diet in a 
percentage of RA patients are associated with improvement in disease activity measures [16]. 
 
Exclusion of lectins: Lectins found in legumes and cereals may act as immunogens, allergens 
and gut irritants and may directly interact with digestive tract bacteria [17] [18].  Foods such 
as beans, wheat, peanuts, peas and lentils, contain lectins and indeed foods commonly 
associated with food allergy such as peanuts and wheat are particularly rich in lectins [5]. 
 
 
Dietary therapy in gout 
For many patients with gout, lifelong hypouricaemic drug treatment is necessary, but for 
some patients, dietary and lifestyle modifications may suffice.  A diet low in animal purines 
(offal, yeast, meat extract and shellfish) may still be prescribed for patients with gouty joint 
inflammation when not adequately controlled by drugs or if medication is unnecessary.  
Alcohol intake should be minimal with the exclusion of beers and fortified wines which 
increase serum uric acid.  Additional non-alcoholic fluids up to two litres a day are advisable 
to avoid dehydration [19] [20]. 
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Dietary therapy in ankylosing spondylitis (AS)  
Nearly all AS patients possess the HLA-B27 gene. Elevated levels of specific antibodies 
against Klebsiella bacteria (found in normal bowel flora) have been reported in AS patients.  
It has been suggested that because Klebsiella possess two molecules which carry sequences 
resembling HLA-B27, microbes may be a trigger for the disease, and that reduction in these 
bowel flora could be beneficial in the treatment of AS.  Bowel microbes depend on dietary 
starch for growth, thus a reduction in consumption of starchy foods has been proposed [21].  
Existing evidence does not support the use of this dietary regime in routine practice [22]. 
 
 
Recommendations 
• A fast followed by a vegan or lactovegetarian diet can have a long-term benefit on 
symptoms of RA for up to 45% of those who follow the regime.  
• 30-40% of RA patients may benefit from an elimination diet followed by a reintroduction 
phase to identify ‘culprit foods’ that they must then avoid.  Some can remain well, off all 
medication and controlled by diet alone, for periods of up to 12 years. 
• A Mediterranean diet may benefit some people with RA.  
• An elemental diet is unlikely to be an appropriate option except for those with food 
intolerance or who cannot tolerate drug treatment. 
• Uninformed and unnecessary dietary restrictions will disturb normal diet and lifestyle 
patterns and increase the risk of nutritional deficiencies. 
 
 
 
BMI and Obesity 
BMI and RA 
Around 15% of RA patients, probably those with the most severe disease are underweight 
[23].  Low BMI in RA patients may be a consequence of ‘rheumatoid cachexia’.  Rheumatoid 
cachexia is characterised by increased catabolism and resting energy expenditure, muscle 
wasting and anorexia and is associated with the production of the pro-inflammatory cytokines 
that play a key role in inflammation-mediated loss of appetite, weight loss and joint 
destruction [24]. 
 
By contrast, 40% of RA patients may be overweight [23], partly because of reduced physical 
activity.  A high percentage of body fat, presenting as obesity, is a known and reversible 
component of CVD, the risk of which is already increased in people with RA.  For a given 
level of body fat, the measured BMI of RA patients was significantly lower than that of 
controls [25].  Thus clinicians might do well to follow the suggestion of Stavropoulos-
Kalinoglou and colleagues [25] of adopting BMI cut-off points 2kg/m2 lower than normal in 
order to decide when to recommend dietary and lifestyle modification in RA patients to 
reduce the risk of cardiovascular co-morbidity. 
 
 
BMI and Gout  
Current guidelines for the management of gout recommend weight loss in those who are 
overweight [19].  A rapid reduction in weight is not advisable as this may trigger an attack of 
acute gout.  Raised serum uric acid is associated with several conditions known collectively 
as the “metabolic syndrome” namely hyperlipidaemia, hypertension, obesity and insulin 
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resistance [26] [27].  These co-morbidities should be addressed by dietary and lifestyle 
modification where possible. 
 
 
BMI and OA 
Obesity is a well-recognised risk factor for development of OA, particularly of the knee and 
hip [3].  High BMI is also associated with more severe disease in terms of the amount of pain 
experienced [28] and the need for joint replacement [29] [30]. 
 
Body weight, joint load and limb malalignment: Weight loss reduces knee-joint loads [31]: 
each pound of weight lost will result in a four-fold reduction in the load exerted on the knee 
per step during daily activities.  Despite this consideration, the effect of body weight on 
disease progression has been less-consistently demonstrated than its effect on disease 
incidence [32].  While some longitudinal studies have shown that obese subjects have a 
higher rate of joint-space loss (assumed to be cartilage loss) compared with non-obese 
subjects, some studies of knee OA have shown no such association with disease progression 
[32].  Results recently published from the Rotterdam Study on 3585 people aged ≥ 55 years 
selected on the basis of the availability of radiographs of baseline and follow-up, showed that 
a high BMI was associated with progression (loss of joint-space width) of knee OA (OR 3.2) 
but not of hip OA [33]. 
 
How do we explain this disparity in findings?  One can intuitively appreciate that the knee 
joint might be more susceptible to loading than the hip joint as found in the Rotterdam Study, 
since it is known that for each 1lb increase in weight, the overall force across the knee in a 
single leg stance increases by 2-3 lb [34].  As for other explanations for disparate results, 
Felson and colleagues [35] cite problems with study design, loss to follow-up, and the 
inclusion of different types of patients.  Furthermore, their results show that as far as OA of 
the knee is concerned, BMI-associated disease progression was related to the degree of limb 
malalignment, the effect being limited to knees in which there was moderate malalignment, 
presumably because of the combination of localised load from malalignment and the excess 
load from increased weight [32]. 
 
Inflammatory mediators from adipose tissue: Clearly the increased mechanical load on 
weight-bearing joints such as the hip, knee or feet resulting from obesity is likely to put extra 
strain on these joints.  However, increase in adiposity is also associated with worsening 
symptoms in non-weight bearing joints such as the hand [35].  This association is probably 
explained by the fact that adipose tissue itself functions as an endocrine organ and is highly 
reactive metabolically, secreting a variety of factors (e.g. leptin, TNF-α, cytokines) with 
inflammatory and other effects [36] [37].  Convincing evidence also exists that obesity is 
associated with the accumulation of macrophages which are responsible for almost all the 
adipose tissue TNF-α expression and the production of major amounts of other inflammatory 
markers [37].  Thus the chronic inflammation associated with high BMI may contribute to 
symptoms.  The good news is that weight reduction is accompanied with an improvement in 
the inflammatory secretory pattern [37]. 
 
It is also important to note that systemic inflammation is associated most strongly with 
abdominal obesity, as visceral fat secretes IL-6 directly into the portal vein and portal vein IL-
6 concentrations correlate directly with arterial CRP in obese subjects.  Thus there is a direct 
link between visceral fat mass in particular and systemic inflammation [38]. 
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A number of studies have indicated that loss of fat mass rather than weight-loss per-se is what 
is important.  Results of a six-week weight control program in 22 OA patients showed that 
both decreasing body fat and increasing physical activity were more important than body-
weight loss or decreasing other indices of obesity in producing symptomatic relief of knee OA 
[39].  To reinforce this message, fat-free mass was found to be beneficially related to knee 
cartilage properties in 297 healthy adults while fat mass had a deleterious effect [40]. 
 
 
Recommendations 
• Overweight or obese RA patients carry more fat mass for the same BMI and may therefore 
require earlier dietary and lifestyle modification to reduce CVD risk. 
• Overweight patients with gout should aim for controlled weight loss.  
• OA patients that are either overweight or obese should participate in weight-loss 
programmes aimed at reducing fat mass, particularly abdominal fat mass [40]. 
• OA patients will need simultaneous exercise programmes that include resistance exercise 
in order to maintain lean muscle mass.  
 
 
Polyunsaturated fatty acids 
Metabolism of PUFAs and formation of eicosanoids 
PUFAs have a number of functions in the body, the most important of which in the context of 
arthritis is that they are precursors of important biological mediators [41].  The interaction 
between n-3 PUFAs and another group of essential fatty acids, the n-6 PUFAs, is central to 
the immunomodulatory function of n-3 PUFAs.  Conversion of the parent n-3 PUFA, α-
linolenic acid (ALA), to long-chain n-3 PUFAs eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), and of the parent n-6 PUFA, linoleic acid (LA), to long chain 
n-6PUFAs, dihomo-γ-linolenic acid (DGLA) and arachidonic acid (AA), involves 
competition for the same enzyme systems (Figure 1[42]).  AA is the precursor of the 
inflammatory series-2 prostaglandins (PGE2) and series-4 leukotrienes (LTB4), whereas EPA 
is metabolised to the less-inflammatory series-3 prostaglandins (PGE3) and series-5 
leukotrienes (LTB5).  Exogenous AA from consumption of meat and meat products leads to 
the formation of inflammatory eicosanoids, the amount produced correlating with 
inflammatory severity in RA [41].  By contrast, the EPA-derived prostaglandins attenuate 
these pro-inflammatory effects and are associated with anti-inflammatory responses [43]. 
 
 
Beneficial effects of long-chain n-3 PUFAs, GLA and DGLA on inflammation 
GLA, DGLA and long-chain n-3 PUFAs are able to decrease pro-inflammatory n-6 
eicosanoid formation if the intake is sufficiently high compared to that of AA, and (to a lesser 
extent) LA.  They do this by decreasing the amount of AA in membrane phospholipids and 
competitively inhibiting the production of AA-derived eicosanoids from COX and 5-LOX 
[44].  For example, when healthy subjects were supplemented with fish oil providing 2.1g 
EPA + 1.1g DHA/d for 12 weeks, the amount of AA in plasma phospholipids and 
mononuclear cells decreased by 20% while that of EPA increased, altering the ratio of 
AA:EPA from 23:1 to 1.5:1 in plasma phospholipids and from 28:1 to 6:1 in mononuclear 
cells [45]. 
 
Other than altered eicosanoid production, long-chain n-3 PUFAs have other anti-
inflammatory effects: they decrease the expression of adhesion molecules, decrease leukocyte 
chemotaxis and both EPA and DHA produce novel anti-inflammatory lipids (resolvins and 
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protectins) [46] [47].  By a combination of such mechanisms, EPA and DHA inhibit 
activation of the transcription factor, NF-κB and the release of inflammatory cytokines [47]. 
However, it has to be noted that not all human studies showed a reduction in inflammatory 
cytokines with dietary long-chain n-3 PUFAs perhaps because of polymorphisms in TNF 
genes that are known to affect the response to dietary fish oil [46]. 
 
 
Interventions with plant oils in RA patients  
GLA is sourced from plant and seeds oils such as evening primrose oil, borage/starflower oil 
and blackcurrant seed oils [48] [49] [50].  Most studies that used between 0.36 and 2.8g/d 
GLA reported improvement in subjective measures including duration of morning stiffness 
and number of swollen and tender joints and also a reduction in use of non-steroidal anti-
inflammatory drugs (NSAIDs).  In one study using 2.8g/d GLA, a statistically significant 
reduction in signs and symptoms of RA disease activity was reported [51].  
 
The long-chain n-3 PUFAs, EPA and DHA, can be synthesised from α-linolenic acid (ALA) 
found most commonly in green leafy vegetables, flaxseed/linseed and canola oils.  However, 
the conversion of ALA to EPA and DHA is relatively inefficient and no good evidence exists 
to support the efficacy of sources of ALA in the management of RA [3] [52].  According to 
Calder [46], more than 10g/d ALA would be required for anti-inflammatory effects to be seen 
and even then, the effects will be much more modest than those exerted by long-chain n-3 
PUFAs.  
 
 
Interventions with fish oil in RA patients 
Fish-oil interventions in RA have been favourably reviewed by a number of authors  though 
none of these reviews was systematic in nature [42] [46] [53] [54] [55].  The doses used in 
fish-oil studies have mostly been from 1-7 g (EPA + DHA)/d, averaging about 3.5 g/d [42] 
[46].    Dependent on the study, significant improvements have been seen in morning 
stiffness, tender joints, swollen joints, patient or physician assessment of disease activity, 
pain, grip strength, NSAID intake and in biochemical parameters, LTB4, IL1, CRP and ESR, 
with a consistent reduction in number of tender joints and duration of morning stiffness in RA 
patients treated for 12 weeks or more with a minimum daily dose of fish oil containing 3g 
EPA/DHA [55]. 
 
Three meta-analyses have been carried out.  The first by Fortin and colleagues showed that 
dietary fish-oil supplementation for three months significantly reduced tender joint count and 
morning stiffness compared with various control oils [56]. 
 
In a subsequent meta-analysis of randomised-controlled trials in RA, MacLean and colleagues 
[43] evaluated 21 studies chosen according to stringent inclusion criteria.  Suggestive benefits 
from fish-oil treatment were found in four outcomes: patient assessed pain, swollen joint 
count, disease activity measured by ESR, and patient global assessment, though none reached 
statistical significance.  However, of seven studies that assessed the effect of fish-oil on 
NSAID requirement among patients with RA, a significant reduction in requirement relative 
to placebo was demonstrated in three, a significant reduction relative to baseline requirements 
in three, and no difference in one [43]. 
 
More recently Goldberg and Katz [47] conducted a meta-analysis of 17 randomized-
controlled trials, 15 of which were in RA, assessing the pain-relieving effects of EPA/DHA in 
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patients with inflammatory joint pain.  Statistically significant benefits were found for patient-
reported joint pain, duration of morning stiffness, number of painful and/or tender joints and 
NSAID consumption following supplementation with n-3 PUFAs for 3-4 months.  Neither 
physician-assessed pain nor Ritchie articular index showed a significant effect [47]. 
 
Thus in summary, all three meta-analyses are in agreement that there are significant beneficial 
effects relating to number of tender joints, duration of morning stiffness, and requirement for 
NSAID treatment, though no significant effect was found on swollen joint count, ESR and 
patient’s global assessment. 
 
 
Interventions with fish oil in RA patients with reduced n-6 PUFA intake 
Fish-oil treatment appears to be more efficacious with a low background AA intake [41] [46].  
Volker and colleagues [57] gave RA patients 40mg/kg body weight/d (2-3g/d) of fish-oil 
containing 60% of n-3 fatty acids for 15 weeks while ensuring that the patients consumed less 
than 10g/d of n-6 PUFA.  After 15 weeks there were significant improvements in the duration 
of morning stiffness, pain score, number of swollen joints, patients’ and physicians’ global 
assessment of disease activity and overall health assessment.  Two further studies that 
restricted the intake of AA (< 90 mg/d) or n-6 PUFA while supplementing with fish oil found 
a significantly reduced number of tender and swollen joints [58] and a reduction in CRP, IL-6 
and TNF-α [59]. 
 
 
Fish oil and OA 
There are no published trials on the effect of n-3 fatty acids in OA, but there is a suggestion 
that long-chain n-3 PUFA supplementation might be beneficial for those with inflamed OA 
joints.  In a small trial carried out in Wales, OA patients supplemented with cod liver oil 
showed reduced COX-2 expression, COX-2 protein levels and the levels of inflammatory 
eicosanoids were reduced in some cases (Prof John Harwood, personal communication, 
2007).  The mRNA expression of the aggrecanase ADAMTS-4, a matrix-degrading enzyme, 
was also reduced. 
 
 
Collateral benefits of increasing the intake of long-chain n-3 PUFAs 
Fish oils rich in n-3 PUFA have also been shown to be effective in secondary cardiovascular 
disease (CVD) prevention [60].  Indeed cardiovascular benefits have been noted at levels 
lower than those required for anti-inflammatory effects (i.e. at EPA/DHA intakes < 1g/d) 
[61].  Given that people with RA are at an increased risk of cardiovascular morbidity 
increasing the intake of long-chain n-3 PUFAs may confer an additional benefit.  
 
 
Sources of fish oils 
Oily fish such as mackerel, pilchards, salmon, trout and herring are the richest source of EPA 
and DHA and make the largest contribution to their intake [62]. 
 
Studies show that an anti-inflammatory effect requires a minimum intake of 3g EPA+DHA/d 
[3].  To achieve this, the number of servings per week, for example, of salmon would be 
around 6-7 portions (average 150g serving).  Six or more portions of fish per week is an 
unrealistic target and may be associated with excessive levels of intake of toxic contaminants 
such as dioxins, polychlorinated biphenyls (PCBs), and mercury [63], so other means must be 
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used to increase tissue levels of long-chain n-3 PUFA.  Fish oil supplements are clearly an 
effective route by which intake of long chain n-3 fatty acids can be increased, either as an 
adjunct to dietary intake [62] or as an optional strategy. 
 
As a generalisation, marine oils come from the fish flesh and contain around 180mg EPA and 
120mg DHA per 1g capsule (i.e. a ratio of 3:2), whereas cod-liver oil comes from the fish 
liver and contains considerably lower quantities of EPA and DHA but also contains vitamins 
A and D [64].  EPA-enriched capsules of fish oil containing a higher ratio of EPA to DHA 
(4:1) are also on sale but at a premium price.  Vitamin E is generally also added to reduce the 
risk of lipid peroxidation of these highly unsaturated oils.  High-strength oils are now 
available and therefore require fewer capsules per day to achieve an effective dose.  Typically 
in a 1g capsule, these high-strength oils contain around 310mg EPA and 210mg DHA.  The 
dose required per day will depend upon the composition of the supplement and on the n-3 
PUFA content of the remainder of the diet.  If no oily fish is eaten, 40 high-strength capsules 
per week would provide the required dose of 21g long-chain n-3 PUFA, i.e. approximately six 
capsules/day.  Based on an intake of two portions of an oily fish per week giving an intake of 
6.5g EPA + DHA/week, an additional 14.5g of long-chain PUFA would be needed which 
would be supplied by an intake of 28 high-strength capsules per week.  Regulations applying 
to the production of fish oil supplements mean that fish oil is a cleaner source of long-chain n-
3 PUFA than oily fish itself [3]. 
 
Cod liver oil is a supplement that is commonly taken within this patient group.  However, the 
n-3 content is quite low (typically 170 mg EPA + DHA) and a large amount would be 
required to produce straightforward anti-inflammatory effects.  Furthermore, in a 1g dose, 
800-1,600µg vitamin A might be provided and it is thought that it may be unsafe to consume 
more than 1.5mg (1,500µg≡ 5000IU)/d of vitamin A on a long-term basis [65].  In particular, 
pregnant women should avoid using cod-liver oil as a means of controlling inflammation 
owing to the known teratogenic effects of vitamin A.  However, 1g of cod liver oil may 
contain 5-8µg vitamin D which may confer benefit (see below). 
 
 
Recommendations 
• RA patients should try to eat two portions of oily fish per week plus four high-strength 
capsules per day for a period of at least three months to see if they experience benefit. 
• If there is a lack of benefit or a worsening in condition, the supplement should be stopped 
as fish oil may interact with TNF genotype to increase production of inflammatory 
mediators [3] [46].  
• Efficacy may be improved by reducing the amount of n-6 PUFA in the background diet.   
• The use of Canola/rapeseed and olive oil and olive-oil based spreads, in place of 
sunflower oil products would lead to a reduction in n-6 PUFA and might offer additional 
symptom relief particularly in the light of the recently-discovered anti-inflammatory 
activity of extra-virgin olive oil [66]. 
• OA patients might be advised to try a similar strategy for a three-month period to see if 
symptoms improve.  
• Additional well designed studies of GLA supplementation are required to establish 
efficacy and dosage before recommendations can be made. 
• Oily fish such as anchovies, herring, mackerel, sardines, sprats are not recommended for 
people with gout because they are a rich source of purines [19]. 
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Dietary antioxidants 
Antioxidant micronutrients such as vitamin C, vitamin E, and the carotenoids may have an 
important role in preventing and/or ameliorating oxidative stress caused by ROS/RNS in the 
inflammatory process. 
 
The main antioxidants that have been studied in arthritic conditions are β-carotene, vitamin C 
and vitamin E.  β-carotene is a powerful antioxidant that is part of the carotenoid family that 
contains the less-well known carotenoids β-cryptoxanthin, zeaxanthin, lycopene and lutein.   
Vitamin E is the most important lipophilic antioxidant, scavenging peroxyl radicals and 
terminating the free-radical lipid peroxidation chain reaction.  It also inhibits arachidonic acid 
(AA) release from phospholipids and reduces eicosanoid formation resulting in a mild anti-
inflammatory effect [41].  Vitamin C has two main functions that are relevant to arthritis: it is 
the most important water-soluble antioxidant in intracellular and extracellular compartments 
but it is also needed for connective tissue synthesis and repair, being required for 
glycosaminoglycan synthesis and by the enzyme lysyl-hydroxylase for the hydroxylation of 
specific prolyl and lysyl residues in procollagen that stabilise the mature collagen fibril.  
Vitamin C is used up in conditions of oxidative stress and so low vitamin C status is common 
in those with rheumatic diseases [54]. 
 
Data from observational studies suggest an effect of antioxidant nutrients on disease 
progression both in inflammatory arthritis and in OA.  Preliminary data suggest that a diet 
rich in antioxidants may dampen down the inflammatory response in early inflammatory joint 
disease [67].  
 
McAlindon and colleagues [68] conducted a prospective observational study of the effect of 
dietary antioxidant nutrients (vitamin C, E and β-carotene) on OA of the knee as part of the 
Framingham Osteoarthritis Cohort Study.  A significant three-fold reduction in risk of OA 
progression, which related predominantly to a reduced risk of cartilage loss, was found for 
both the middle and the highest tertile of vitamin C intake.  Those with high vitamin C intake 
also had a significantly-reduced risk of developing knee pain.  A significant though less-
consistent reduction in risk of OA progression was also seen for β-carotene. 
 
 
Trials of antioxidant supplements of in arthritis 
A recently-published systematic review of randomized clinical trials (RCTs) of antioxidant 
vitamins A, C, E and selenium (Se) in the treatment of arthritis identified 20 unique RCTs 
meeting the inclusion criteria: 11 in inflammatory arthritis and 9 in OA [69].  Excluding Se 
which is dealt with separately below, there were five trials of vitamin E in inflammatory 
arthritis and seven in OA.  One RCT suggested superiority of vitamin E over placebo and 
three RCTs suggested equivalence between vitamin E and diclofenac in the treatment of 
inflammatory arthritis: vitamin E supplementation appeared to reduce pain [70] [71] [72].  In 
OA, four RCTs compared vitamin E with placebo. Two shorter-term studies were positive 
and two longer-term studies were negative.  Two further RCTs suggest equivalence between 
vitamin E and diclofenac in the treatment of OA.  There was an isolated positive result for 
vitamin C in OA. 
 
The authors report that as the studies included are generally of poor quality, there is no robust 
evidence that antioxidant vitamins are effective in any type of arthritis.  They recommend that 
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the positive effect of vitamin E on pain in some shorter-term studies of OA and inflammatory 
arthritis needs to be tested in RCTs using more methodologically robust protocols [69]. 
 
 
Recommendation 
• Ensure an adequate daily intake of dietary antioxidants (see Table 2) [73]). 
• A modest vitamin C supplement might be advised for those with OA if dietary intake is 
low. 
• RA patients might try a vitamin E supplement (up to 400 mg/d) for up to three months to 
see if pain is diminished. 
• There is no scientific evidence to support the practice of mega-dosing with nutritional 
supplements.  High doses of individual nutrients can be harmful.  
 
 
Selenium 
Functions of selenium relevant to RA and OA  
The potential of selenium to affect RA can be understood from the following Se-associated 
effects: 
- Antioxidant selenoenzymes, such as glutathione peroxidise (GPx) reduce lipid 
hydroperoxides (or H2O2) to harmless alcohols (or H2O) thus reducing oxidative stress 
[74]. 
- GPxs can modulate the production of biologically active eicosanoids by the COX and 
LOX pathways [74]. 
- Se down-regulates the expression of inflammatory genes [75]. 
- Selenoprotein P scavenges the powerful inflammatory agent peroxynitrite which is 
produced in inflamed joints [54] [76]. 
- Selenium may reduce the ability of matrix metalloproteinases (MMPs) to cause cartilage 
breakdown by inducing tissue inhibitors of MMPs (TIMPs) [77]. 
- Selenium may inhibit neovascularisation which is central to the development and 
perpetuation of rheumatoid synovitis [78] [79]. 
 
 
Selenium status in OA and RA patients  
Low concentrations of selenium have been measured in plasma or serum of RA patients from 
different parts of the world when compared to controls, reflecting the observed association 
between selenium concentration, clinical indices of disease activity and biochemical 
parameters of inflammation [3]. 
 
Only one study, described as a preliminary account, has evaluated selenium status in OA 
patients [79].  Selenium status in 940 newly enrolled participants was found to be lower in 
those with radiographically determined knee OA, bilateral knee OA and severe knee OA (p ≤ 
0.05) than in those with normal X-rays.  For those in the highest compared to the lowest 
tertile of toenail selenium, the odds (95% CI) of knee OA were 0.62 (0.37, 1.02), for bilateral 
knee OA 0.79 (0.31, 0.97), and severe knee OA 0.56 (0.34, 0.94), suggesting that selenium 
may be a potentially modifiable risk factor for OA. 
 
 
Intervention studies with selenium 
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Of seven randomised trials of selenium supplementation in RA [3], three reported significant 
improvements in measurable parameters of disease activity.  In the first, a dose of 200 µg/d 
showed significant beneficial changes in the selenium group for pain at three months and 
number of joints involved at three and six months [80].  The second study used the same dose 
but both Se and placebo groups also received fish oil fatty acids at 30 mg/kg body weight 
[81].  At the end of three months, fewer tender or swollen joints, morning stiffness and a 
reduction in steroid and NSAID use were reported.  The third trial using a higher dose (600 
µg selenium as selenium-enriched yeast) found no significant effect at four months but a 
significant improvement at eight months in articular pain index, grip strength and morning 
stiffness [82].  However, a recent systematic review of trials of antioxidant vitamins and 
selenium in arthritis has pointed out that the trials are methodologically weak, in particular 
presenting no between-group statistical comparisons from which proper assessment of the 
treatment effect can be made [69].  Thus satisfactory randomised controlled trial evidence for 
a benefit of selenium in RA is currently lacking. 
 
 
Recommendations for selenium intake 
• Recommended daily intakes (average 53µg/d for women and 60µg/d for men) are not 
currently achieved in the majority of European countries together with parts of China [83]. 
• RA patients appear to have lower selenium status than healthy individuals and a greater 
requirement for antioxidants owing to the oxidative stress and inflammation associated 
with their condition [3]. 
• As selenium is found in good concentrations only in a small number of foods [84] - Brazil 
nuts, organ meats and fish (Table 2) - supplementation should be considered [41]. 
• A daily supplement of 50-100µg would be realistic though Adam [41] has suggested that 
an intake of 300µg/d is necessary to improve the status of RA patients.  
• Supplements containing 100 or 200 µg are readily available and have been associated with 
health benefits in many studies [84]. 
 
 
 
Copper, zinc and RA and OA  
Functions of copper and zinc relevant to RA and OA  
Zinc and copper are key components of important metalloenzymes.  Dietary deficiency of 
either copper or zinc will markedly decrease tissue concentration of the cytosolic antioxidant 
enzyme, superoxide dismutase (CuZnSOD) resulting in peroxidative damage to the joint [85]. 
 
Zinc metalloenzymes such as MMPs are involved in the degradation of connective tissue and 
cartilage breakdown [86].  Copper on the other hand has a key role in building the 
extracellular matrix by cross-linking proteins such as collagen and elastin to give them 
structural integrity [87].  Copper and zinc act in concert to maintain connective tissue.  
However, on the negative side, copper is required for angiogenesis and its chelation 
suppresses RA [88] and adjuvant-induced arthritis [89].   
 
 
Copper and zinc status in OA and RA patients  
A five-day dietary survey of 48 RA patients in New Zealand suggested that only 10% 
achieved the recommended dietary intake of zinc [90].  Low serum zinc has certainly been 
reported in RA patients [90] [91], but it may be more likely to be a consequence of 
inflammation and disease activity than of reduced dietary intake [91].  In inflammatory 
 14
rheumatic diseases, the operation of the acute phase response causes redistribution of the 
element within body compartments, such that there is a decrease in plasma zinc and an 
increase in plasma copper [93]. 
 
However, CuZnSOD activity has been found to be significantly lower in RA patients [94] 
[95].  Such data suggest that there might be some benefit in increasing the activity of this 
enzyme that can remove superoxide. 
 
 
Intervention studies with copper and zinc 
Studies have looked at the effects of zinc supplementation on clinical outcomes of RA.  High-
dose zinc has been shown to improve symptoms in one study [96] but not in others [91] [41].  
Naveh and colleagues carried out a zinc supplementation study in RA patients: the results 
suggest zinc malabsorption and therefore zinc deficiency in the RA patients [92].  
Malabsorption may be the reason why no benefits were seen after zinc supplementation [91]. 
 
Early uncontrolled work on copper supplementation in RA reported beneficial effects [82].  A 
later study by DiSilvestro and colleagues [94] administered 2mg of copper/d for four weeks to 
23 RA subjects and 47 matched controls.  Before supplementation, erythrocyte CuZnSOD-
activity was significantly lower in RA patients than in controls but increased in 18 out of 23 
RA patients following supplementation, suggesting "marginal copper status in RA patients" 
[94]. 
 
Intra-articular injections of CuZnSOD have been shown to reduce joint inflammation and 
provide benefit in both RA and OA suggesting the need for adequate intakes of both of these 
micronutrients [82] [54]. 
 
 
Zinc and copper status 
The need for concerted synthesis and degradation of connective tissue in addition to the role 
of both zinc and copper in SOD, suggest the need for adequate intakes of both of these 
micronutrients.  It is therefore of some concern that in the latest UK National Diet and 
Nutrition Survey of people aged 65 and over, the intake of copper fell below the RNI in 82% 
of free-living participants and in 90% of those in institutions, while the corresponding figures 
for zinc were 62% and 54% [97].  Though intake figures were better in the survey of younger 
adults, even then, median copper intake was below the RNI in women (82% of RNI) [98]. 
 
Recommendations for intake of copper and zinc in RA and OA 
• Dietary intake of copper and zinc should reach the RDA/RNI level (copper 0.9-1.2mg/d; 
zinc 9.5-11mg/d men, 7-8mg/d women). 
• Good food sources of zinc and copper are shown in Table 2. 
• Given the potential of copper to catalyse redox reactions producing the hydroxyl radical, 
supplementation with copper above RDA/RNI levels is to be avoided while doses of zinc 
more than twice the RDA/RNI may impair copper absorption [99]. 
 
 
Iron in RA and OA 
Functions of iron relevant to RA and OA  
In active RA, the inflamed synovium is subject to recurrent traumatic microbleeding and iron 
is deposited as ferritin in the synovium [100].  The ischemia-reperfusion cycles that occur 
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within the inflamed joint lead to the production of superoxide (O2˙-) which can mobilise iron 
from ferritin.  Free iron (or haem) has the capacity to form the highly toxic and destructive 
hydroxyl radical from O2˙- and hydrogen peroxide by the Fenton reaction causing tissue 
damage within the joint [100].  Thus a high iron status is contraindicated in OA and RA 
patients. 
 
 
Iron status in arthritic patients 
Anaemia is a common co-morbidity in individuals with RA, mild anaemia being present in 
between 33% and 60% of patients [101].  This may be iron-deficiency anaemia resulting from 
gastrointestinal bleeding provoked by the use of NSAIDs, but around 60% of the time in RA 
patients, it is anaemia of chronic disease which is associated with the severity of the condition 
[102] [103].  In the latter case, there will be low levels of plasma iron despite packed iron 
stores [41].  Haematological tests (see [3]) should be used to distinguish those RA patients 
whose anaemia might benefit from simple iron therapy from those with anaemia of chronic 
disease (or folic acid/vitamin B12 deficiencies) who require different treatment. 
 
 
Recommendations for iron intake 
• Ensure that dietary intake of iron is adequate.  
• As high iron status may be detrimental, worsening inflammation, iron supplements should 
not be given unless there is evidence of a true deficiency.   
 
 
Vitamin D 
Vitamin D may come from the diet (vitamin D2 in foods of plant origin, vitamin D3 in foods 
of animal origin) or from the action of sunlight (UVB) on the skin (vitamin D3).  It is 
converted into 25-hydroxyvitamin D [25(OH)D] in the liver and to the active D-hormone, 
1,25-dihydroxyvitamin D [1,25(OH)2D] by further hydroxylation in the kidney, though 
several other tissues also possess the enzyme, 1α-hydroxylase, allowing local production of 
1,25(OH)2D (Figure 2, [104]).   
 
While the role of vitamin D in calcium homeostasis and maintenance of skeletal health is well 
recognised, it is less well known that vitamin D or its metabolites have important effects on 
muscle function and the immune system [105].  Receptors for 1,25(OH)2D (VDR) are present 
in more than 30 different tissues [104] while VDR polymorphisms have been found to be 
associated with the occurrence [106], time of onset [107], severity [108] and accelerated bone 
loss [109] in RA and with risk of early knee OA [110] and presence of osteophytes [111].  
Evidence for the importance of vitamin D in RA and OA is assessed below. 
 
Vitamin D in RA 
If vitamin D levels are inadequate, the immune system tends towards the development of self-
reactive Th1 cells and autoimmunity [112].  In support of this assertion, a significant inverse 
association was found between vitamin D intake and RA risk in a prospective study of 30,000 
women (the Iowa Women’s Health study) [113]. 
 
Partly as a result of inhibition of renal 1-α-hydroxylase by TNF-α, people with inflammatory 
diseases exhibit markedly reduced circulating concentrations of D-hormone [105] which have 
been shown to correlate with the extent of RA disease activity.  In 96 RA patients grouped 
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according to disease activity, serum concentration of 1,25(OH)2D correlated negatively (P < 
0.001) with disease activity both in patients with and without glucocorticoid treatment [114].   
 
A high-quality, recently-published study backs up these findings.  In 206 consecutive patients 
with newly diagnosed inflammatory polyarthritis (IP) enrolled in the Norfolk Arthritis 
Register, an inverse relationship was found between baseline 25(OH)D and tender joint count, 
DAS28 and HAQ score [115].  At 1 year, there was a significant inverse association between 
baseline concentrations of both 25(OH)D and 1,25(OH)2D and the HAQ score and a 
significant inverse association between 25(OH)D and tender joint count.  The strength of this 
study is that patients were evaluated early after disease onset, had not been treated with 
steroids and were either not treated with DMARDs or had taken them for less than 6 weeks. 
 
Though supplementation with 1,25(OH)2D in autoimmune animal models of RA markedly 
suppressed disease activity [116], human trials of vitamin D or its metabolites in RA have not 
shown such a clear outcome.  Of five small intervention studies [104], three showed a 
significant improvement in disease activity or pain.  Those that showed benefit used high 
doses of vitamin D (2500µg/d =100,000IU/d) [117] or 50µg/d 25(OH)D [118] or 2µg/d of the 
synthetic 1,25(OH)2D precursor, alfacalcidol [1α(OH)D3] [119].  The relatively disappointing 
findings of these small intervention studies may well be a consequence of the inhibition of 
renal 1-α-hydroxylase by TNF-α, resulting in poor conversion to the active hormone, 
1,25(OH)2D [105].  Thus there may be a case for the treatment of RA patients with a synthetic 
vitamin-D hormone such as alfacalcidol in cases where vitamin D cannot be metabolised 
effectively. 
 
In fact the argument for increasing vitamin D intake in RA patients can be made 
independently on other grounds: on the basis of its bone-sparing effects; its pleiotropic effects 
on other autoimmune diseases, muscle function, cancer risk, cardiovascular disease and 
diabetes; and the wide prevalence of vitamin D deficiency not only in RA patients but in the 
general population as described below [104] [120] [121].  
 
 
Vitamin D and OA 
Vitamin D appears to be able to stimulate the synthesis of proteoglycan by articular 
chondrocytes [122].  The effect of vitamin D was investigated within the Framingham OA 
Cohort study [123].  In the 556 participants that had complete assessments, a three- to four-
fold significantly-increased risk of progression of radiographically-determined OA, was seen 
in the middle and low tertiles of vitamin D intake and serum concentration [122].  
Furthermore, the ‘Study of Osteoporotic Fractures Research Group’ showed that high serum 
concentration of vitamin D protected against both incident and progressive hip OA [124]. 
 
However more recent results from two longitudinal cohort studies, the Framingham Offspring 
cohort (715 subjects) and the Boston Osteoarthritis of the Knee Study (BOKS) (277 subjects) 
[125] found no association of baseline 25(OH)D concentration with radiographic worsening 
of joint space narrowing nor any relationship with cartilage loss.   
 
Though the evidence is contradictory for OA, the wide prevalence of vitamin D deficiency 
and the broad range of important roles played by vitamin D suggest that even OA patients 
should be encouraged to optimise their vitamin D status as outlined below [104] [120] [121]. 
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Vitamin D and osteoporosis in RA and OA 
Patients with RA are at an elevated risk of developing osteoporosis [126].  A significant 
positive association has been observed between serum 25(OH)D and bone density in OA 
patients [127].  Vitamin D inadequacy is particularly common in patients with osteoporosis 
[121].  While vitamin D supplementation has been suggested as having the capacity to 
enhance bone mineral density in OA patients, plain vitamin D is not as effective as the 
synthetic vitamin D hormone, alfacalcidol, which improves bone and muscle metabolism and 
clinical symptoms in patients with RA [105]. 
 
 
Vitamin D status 
As the main source of vitamin D is from the action of sunlight on the skin, Vitamin D 
deficiency is widespread in people living at latitudes where the sun’s rays (UV-B) do not have 
enough power to penetrate the skin to trigger vitamin D synthesis and in those who spend 
little time outdoors [121] [104].  UV-B radiation is negligible from October to April at 
latitude 520N and from November to February at 420N [104].  Furthermore, vitamin D 
synthesis is markedly reduced in elderly skin, in dark skin, when enveloping clothing is worn 
or when sun-tan cream is applied.  Vitamin D status is measured by the serum concentration 
of 25(OH)D.  Several studies have reported that 40-100% of European and US elderly men 
and women living in the community are deficient in vitamin D, as defined by a level of 
25(OH)D < 50 nmol/L (≡ 20ng/ml) [121].  A concentration of 52-72 nmol/L can be 
considered to indicate relative insufficiency of vitamin D whereas a level ≥ 75 nmol/L 
indicates sufficiency [121].  A recent study of 45-year old British adults showed a high 
prevalence of hypovitaminosis D during the winter and spring, when 25(OH)D concentrations 
<25, <40, and <75 nmol/L were found in 15.5%, 46.6%, and 87.1% of participants, 
respectively [120]. 
 
Vitamin D status is lower in vegetarians than in omnivores and fish eaters and is particularly 
low in vegans [3].  As vitamin D is fat-soluble, it tends to go to ground in fatty tissue, 
removing it from the circulation and creating a state of deficiency or relative deficiency in 
overweight or obese people [121]. 
 
 
Sources of vitamin D  
Food sources of vitamin D are few and many people do not eat them (Table 2).  Oily fish 
such as salmon, mackerel and sardines are by far the best sources, supplying from 360-
1000IU (8-25 µg) per portion [3].  Dried shiitake mushrooms (1600 IU/100 g) are a very rich 
source though an unusual dietary component in the West.  One egg yolk supplies 
approximately 20 IU.  In the US, milk, which is fortified, makes the biggest contribution to 
vitamin D intake while orange juice is also frequently fortified [3].  Though margarines are 
fortified in many countries, they seem to make little contribution to vitamin D intake [120].  
Cod liver oil can supply 400-100 IU/teaspoon but its high vitamin A content makes it 
unsuitable for consumption in pregnancy [121] [3].  Vitamin D supplements may provide 
cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2), though the latter is only 20-40% 
as effective in maintaining 25(OH)D levels [128]. 
 
 
Recommendations 
• Patients with RA (and even those with OA) who do not have adequate sun exposure 
should be recommended to ensure that they have frequent meals of oily fish, a good 
vitamin D source. 
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• RA patients who do not eat oily fish should supplement with 1000-2000IU (25-50µg)/d as 
cholecalciferol (vitamin D3).  (Cod-liver oil is an alternative source and contains 5-8µg 
vitamin D3/g.)  
• Vegetarians or vegans will prefer to supplement with vitamin D2 (ergocalciferol) but will 
need to increase the dose three-fold. 
• If in doubt as to whether vitamin D status is adequate, have serum 25(OH)D measured.  
The value should reach 75nmol/L [121]. 
• Though patients with failing kidneys or kidney disease may additionally require a 
synthetic D-hormone analogue such as alfacalcidol, this will not replace the need for 
vitamin D as a source of 25(OH)D for local conversion in tissues [121]. 
 
 
Summary 
Dietary manipulation may benefit a significant subset of RA patients whether it be by 
adopting a vegan, lactovegetarian or Mediterranean diet or by avoiding culprit foods 
identified with the help of an appropriate health professional.  Overweight/obese RA patients 
require dietary and lifestyle modification to reduce CVD risk while those with gout need 
controlled weight loss.  Weight-loss programmes for overweight or obese OA patients must 
reduce fat mass without losing lean muscle.  Patients with inflammatory joint disease (other 
than gout) may benefit from increasing their intake of n-3 PUFA from oily fish and/or fish-oil 
supplements.  Reducing the background intake of n-6 PUFA by replacing 
sunflower/safflower/corn/soybean oils by Canola/rapeseed and olive oil products should 
improve efficacy.  A good daily intake of dietary antioxidants is important to counteract the 
oxidative stress associated with inflammatory joint disease and there is some evidence that 
pain in RA patients may be improved by a vitamin E supplement.  OA progression has been 
shown to be lower in OA patients with good vitamin C intake.  RA patients appear to have 
lower selenium status than healthy individuals.  Selenium has recognised anti-inflammatory 
effects but European selenium status is low.  Though adequate copper and zinc status is 
important for the maintenance of connective tissue, high iron status may be detrimental.  
Vitamin D is an important nutrient for bone health and musculoskeletal function.  Populations 
in northern Europe who do not eat much oily fish will require vitamin D supplementation.   
Important co-morbidities may also respond to dietary modification: the risk of CVD, 
metabolic syndrome, obesity and underweight may be reduced. 
 
 
 
Practice points  
• A fast followed by a vegan or lactovegetarian diet can have a long-term benefit on 
symptoms of RA for up to 45% of those who follow the regime while a Mediterranean 
diet may benefit a sub-group of RA patients. 
• A sub-group of RA patients may benefit from a professionally-supervised elimination diet 
followed by a reintroduction phase to identify ‘culprit foods’ that they must then avoid:  
however uninformed and unnecessary dietary restrictions will disturb normal diet and 
lifestyle patterns and increase the risk of nutritional deficiencies. 
• Overweight or obese RA patients carry more fat mass for the same BMI and may therefore 
require earlier dietary and lifestyle modification to reduce CVD risk. 
• Overweight patients with gout should aim for controlled weight loss.  
• Overweight or obese OA patients should participate in weight-loss programmes aimed at 
reducing fat mass and in simultaneous exercise programmes to avoid loss of lean muscle. 
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• RA patients should try to eat two portions of oily fish per week plus four high-strength 
fish-oil capsules per day for a period of at least three months to see if they experience 
benefit while OA patients with joint inflammation could also be advised to increase their 
intake of oily fish or try treatment with fish oil/cod liver oil for a three-month period to see 
if symptoms improve.  Efficacy may be improved by reducing the amount of n-6 PUFA in 
the background diet.   
• Patients should ensure a good daily intake of dietary antioxidants.  OA patients may need 
a modest vitamin C supplement if dietary intake is low.  RA patients might try a vitamin E 
supplement (up to 400 mg/d) for up to three months to see if pain is diminished. 
• RA patients appear to have lower selenium status than healthy individuals and a greater 
requirement for antioxidants owing to the oxidative stress and inflammation associated 
with their condition.  As selenium status is low in Europe and few foods are good 
selenium sources, supplementation up to 200 µg/d should be considered. 
• Dietary intake of copper and zinc should reach the RDA/RNI level (see 
Recommendations).  Iron supplements should not be given unless there is evidence of a 
true deficiency.   
• Patients with RA (and even those with OA) who do not have adequate sun exposure or do 
not eat oily fish will require a dietary vitamin D supplement (see Recommendations). If in 
doubt as to whether vitamin D status is adequate, have serum 25(OH)D measured.   
• There is no scientific evidence to support the practice of mega-dosing with nutritional 
supplements.  High doses of individual nutrients can be harmful.  
 
   
 
Research agenda  
• Nutritional interventions in patients with less-severe/early disease appear to have had 
more success.  Such studies are needed to investigate the influence of diet on disease 
course.   
• Further investigation of the efficacy of vitamin E supplementation is warranted, 
particularly of γ-tocopherol as it (and its major metabolite) is a much stronger anti-
inflammatory agent than α-tocopherol.               
• High quality trials of selenium and vitamin D supplementation are needed in RA and OA 
with pain and functionalityas the primary outcome measures. 
• Detailed investigations of the influence of background diet on patients’ response to 
medication are warranted. 
• Future dietary interventions should include genetic testing where relevant polymorphisms 
may exist or at the very least, samples should be laid down for DNA isolation and later 
genotyping wherever possible.   
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Table 1: Foods found most likely to cause intolerance reported by Darlington and Ramsey 
[5]. NB: Dietary intolerances vary markedly from one individual to another and must be 
determined individually for each patient by an elimination diet followed by a reintroduction 
phase under the guidance of a health professional (reproduced with permission from Oxford 
University Press).  
 
Food Symptomatic patients 
affected by food (%) 
Food Symptomatic patients 
affected by food (%) 
Corn 57 Malt 27 
Wheat 54 Cheese 24 
Bacon/pork 39 Grapefruit 24 
Oranges 39 Tomato 22 
Milk 37 Peanuts 20 
Oats 37 Sugar (cane) 20 
Rye 34 Butter 17 
Eggs 32 Lamb 17 
Beef 32 Lemons 17 
Coffee 32 Soya 17 
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Table 2: Rich food sources of specific nutrients of relevance to RA/OA (data from [73]) 
 
Vitamin C Vitamin E Carotenoids Selenium Copper Zinc Vitamin D 
 
Blackcurrants, 
kiwi fruit, 
strawberries 
Vegetable 
oils 
Carrots, 
mange tout 
peas, curly 
kale, sweet 
potato 
Brazil 
nuts 
Crab, 
prawns, 
lobster, 
mussels 
Red 
meat 
Oily fish esp. 
mackerel, 
kippers, herring, 
pilchards, trout 
salmon, sardines 
Citrus fruits Margarine Red/green 
capsicums, 
Kidney Liver Liver Dairy products 
Fruit juice Wholegrain 
cereals 
Tomato 
products 
Liver Kidney Kidney Eggs 
Vegetables esp. 
curly kale, spring 
greens, Brussels 
sprouts, green 
and red 
peppers/capsicum 
Nuts and 
seeds 
Melon 
(orange), 
apricots, 
pumpkin 
 
Fish Plain 
chocolate 
Fish and 
shellfish 
Margarine and 
butter 
Potatoes, sweet 
potato 
Fried foods Mango, 
guava, 
passion fruit 
Shellfish Beans 
and 
lentils 
Milk 
and 
milk 
products 
Meat 
Potato chips Meat, fish, 
eggs 
Oranges, 
tangerines  
Lentils 
and 
pulses 
Brazil 
nuts 
Pulses Cereal products 
 
 
 
 
 
 
Figure legends 
 
Figure 1: Desaturation and chain elongation of essential fatty acids 
 
Figure 2: Vitamin D metabolism (adapted from [104]) 
 
 
